Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Confirms aspirin's clear benefit in secondary prevention; challenges routine primary prevention use given uncertain net value.
Web Table 1: Baseline characteristics of the primary and secondary prevention trials Number of participants Male Age, years Blood pressure (SBP/DBP), mmHg Total cholesterol, mmol/L Current smokers Body mass index, kg/m 2 Diabetes mellitus Hypertension Any vascular disease Primary prevention trials
No takes yet. Share an insight, caveat, or question.
A 2009 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: